Pegargiminase

DB06592InvestigationalSmall molecule

Pegargiminase is an anticancer agent.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in melanoma and hepatocellular carcinoma.Curator reviewed
Also known as
ADI PEG20 · ADI-PEG 20 · Arginine deiminase pegylated · Pegylated arginine deiminase

Resolves to

Compound
UNII0B7PYQ9YRTCAS1394129-74-8

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
35Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Pegargiminase, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In